X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (699) 699
female (462) 462
febrile neutropenia (452) 452
index medicus (438) 438
neutropenia - chemically induced (425) 425
oncology (417) 417
middle aged (384) 384
male (373) 373
chemotherapy (338) 338
aged (337) 337
adult (323) 323
antineoplastic agents - adverse effects (311) 311
cancer (270) 270
neutropenia (270) 270
neoplasms - drug therapy (225) 225
antineoplastic combined chemotherapy protocols - adverse effects (213) 213
risk factors (167) 167
colony-stimulating factor (159) 159
febrile neutropenia - chemically induced (159) 159
granulocyte colony-stimulating factor - therapeutic use (157) 157
antineoplastic combined chemotherapy protocols - therapeutic use (146) 146
retrospective studies (144) 144
treatment outcome (141) 141
fever (127) 127
aged, 80 and over (126) 126
hematology (126) 126
neutropenia - drug therapy (121) 121
medicine & public health (120) 120
filgrastim (118) 118
neutropenia - prevention & control (118) 118
adolescent (115) 115
fever - chemically induced (111) 111
pharmacology & pharmacy (111) 111
antineoplastic agents - therapeutic use (104) 104
breast neoplasms - drug therapy (101) 101
prospective studies (99) 99
care and treatment (97) 97
granulocyte colony-stimulating factor (91) 91
child (90) 90
breast-cancer (87) 87
cancer-patients (87) 87
anti-bacterial agents - therapeutic use (81) 81
mortality (80) 80
non-hodgkins-lymphoma (80) 80
health care sciences & services (78) 78
neutropenia - complications (76) 76
therapy (76) 76
breast cancer (75) 75
neoplasms - complications (74) 74
polyethylene glycols (74) 74
antineoplastic combined chemotherapy protocols - administration & dosage (73) 73
pegfilgrastim (71) 71
young adult (71) 71
drug administration schedule (70) 70
granulocyte colony-stimulating factor - administration & dosage (68) 68
nursing (68) 68
analysis (67) 67
rehabilitation (67) 67
cell lung-cancer (65) 65
child, preschool (65) 65
g-csf (64) 64
risk (64) 64
chemotherapy-induced neutropenia (61) 61
risk assessment (60) 60
management (58) 58
recombinant proteins (58) 58
double-blind (57) 57
health aspects (57) 57
prognosis (57) 57
prophylaxis (55) 55
pediatrics (54) 54
research (54) 54
single-administration pegfilgrastim (54) 54
incidence (53) 53
infection (52) 52
multicenter (52) 52
children (50) 50
docetaxel (50) 50
dose-intensity (50) 50
pain medicine (49) 49
rehabilitation medicine (49) 49
hematology, oncology and palliative medicine (48) 48
toxicity (48) 48
cyclophosphamide - administration & dosage (47) 47
fever - drug therapy (47) 47
fever - etiology (47) 47
induced febrile neutropenia (47) 47
drug therapy (46) 46
medicine, general & internal (46) 46
neutropenia - epidemiology (45) 45
daily filgrastim (44) 44
dose-response relationship, drug (44) 44
granulocyte colony-stimulating factor - adverse effects (44) 44
guidelines (44) 44
trial (44) 44
cancer patients (43) 43
solid tumors (43) 43
time factors (42) 42
antineoplastic agents (41) 41
doxorubicin - administration & dosage (41) 41
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (675) 675
Japanese (9) 9
French (8) 8
German (8) 8
Spanish (6) 6
Hungarian (2) 2
Chinese (1) 1
Lithuanian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 2014, Issue 10, p. CD003039
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 6, pp. 743 - 754
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2006, Volume 24, Issue 19, pp. 3187 - 3205
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Drugs, ISSN 0012-6667, 02/2009, Volume 69, Issue 3, pp. 361 - 392
Journal Article